Xencor Inc. announced the issuance of U.S. Patent 12,492,253, covering its Xtend™ Fc domain technology for extending the half-life of antibodies targeting C5. The new patent extends the term for this technology into December 2028, approximately three years beyond the previous latest-to-expire U.S. patent for the Xtend Fc domain. This extension also prolongs the U.S. royalty term for Ultomiris® by about three years, with Xencor expecting to receive low-single digit royalties on net sales of Ultomiris through December 2028. The company estimates potential royalty revenue in excess of $100 million to $120 million in aggregate for the extended patent term.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xencor Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251209345770) on December 09, 2025, and is solely responsible for the information contained therein.